Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is it silence?
My personal opinion is that they are very different, however, the MOA of A2-73 provides benefit through similar pathways. Rhett children have a different set of issues, and in my opinion A2-73 provides a little bit of balance. I also beleive a "cocktail" therapy will be required, but that A2-73 could play a major role in advancements by addressing some of the most notable and painful "not actual pain but heartfelt" effects.
I agree. It would be like saying antibodies have no function.
It sound like a translation issue. His basis is incorrect as stated and there are several scholarly articles to support that (which he references later). S1r is a chaperone protein, that does not mean it has no function; and every time they miss the key important factors of muscarinic receptors.
I would expect that most investors do not read a bunch of articles about sigma 1 receptors, like this board, and as the mouthpiece of the organization, that was a poor response. The moderator was probably bored because they already went over the discussion points, but the rhetoric was wrong.
has no purpose in the body
Thanks for reminding me. I was getting this confused with every other investment, forgot this was AVXL for a second.
Or planes that big aren't meant to fly.
S1 has no immediate function for day to day activities in our bodies. It can be left out and animals have no different life. It seems to only be useful later in life, for activation by certain small molecules.
Great, more time for dilution. The results are imminent on this iceberg, but it is the best thing since sliced bread... Nobel worthy.
Did the fireside chat happen yet? Waiting for the ground breaking surge in share price. Did he deliver results, or are we waiting on the imminent as usual?
Although if I remember correctly this is a tip of an iceberg. I guess relatively a couple of years would be screaming fast for an iceberg.
Isn't this the same format they have attended previously. If I recall, last time it was a flop.
I agree with this.
Define relative worth. You could argue that in a free market relative worth is equal to the share price of the stock at that instant in time, but what happens if the share price drops, or increases later? When you add shares at the market price, you would always increase the relative worth of the stock by the sale price at that instant (market cap). Often dilution comes at a discount though.
Since there is no revenue, this stock is relatively worthless right now, aside from real property the intellectual property is unproven. At the time the company starts to generate revenue, you could measure relative worth. So right now, when the company adds shares they are decreasing the burden of operational expenses, and that is only worth something if revenue is created from the expense. You could measure worth in some other form like a humanitarian adder, but this is an investment and to date there has been no return on investment, making it relatively worthless.
So if the relative worth is zero, is it dilution if you add more shares?
Some will describe dilution as a necessary evil and to look the other way as long as the share price increases. This doesn't make sense unless they have an interest in the dilution. As an investor you should want to maximize your investment through fiscally responsible expenditure. If the company dilutes and spends or gives up 95% of the added value irresponsibly, yet you still make 5%, does that sound reasonable? No.
Just my opinion, not that you asked for it. Is it dilution if the share price drops but no shares are added? How are you defining real value and relative worth?
To say this again... on topic, your reply us non sequitur. Your post is in response to mine.
The FDA has enforcement responsibility, period. The drug does not need to be approved, and the trial does not need to be conducted in the US.
https://www.natlawreview.com/article/release-new-guidance-fda-signals-it-s-serious-about-enforcing-clinical-trial-data
If someone is claiming a grand slam, the FDA has the option to question the legitimacy of the claim, especially if they aren't in the loop.
FDA Signals it is Serious about Enforcing Clinical Trial Data
FDA Signals it is Serious about Enforcing Clinical Trial Data
Yes, it does.
That’s why Congress passed the Food and Drug Administration Amendments Act (FDAAA) in 2007: to help prevent such tragic mistakes. It’s a transparency law, one that requires companies, universities, and government labs that sponsor important clinical trials to reveal the results to patients, physicians, and independent researchers.
On paper, the FDAAA makes it illegal for trial sponsors to cherry-pick results, meaning publishing favorable results (like data showing safety and effectiveness) while withholding unfavorable ones (like data showing toxicity or lack of effectiveness). If independent researchers have access to all of the data from all trials — favorable and unfavorable — they can double-check the work of the FDA and help keep the public informed.
Really?
Good Documentation Helps When FDA Knocks on Door
Oh, what to do.
I hope A2-73 is a treatment for all of these terrible diseases, don't get me wrong. Only time will tell, and I hope the trials are scrutinized before presenting this hope to needy patients. This is different than investing, and they often get crossed. It is OK to wish and hope for a successful treatment, it is not OK to try and push a drug to market without scrutiny and consideration of all trial information, that is greed, not compassion.
They may be shouting from the crowd, but they leave doubt. The SEC rules to this point have been used as an excuse, not by the company. If the results were a grand slam, the FDA will be knocking on Anavex's door.
We as investors were only given partial data, so believe what you will. The end game is to get to market, with all factors considered.
Another post explained hiring new positions... why has Anavex not presented a plan to get to market involving key positions? More shouting from the crowd.
Understood, your perspective makes more sense.
That's great. It obviously has not been enough for many others.
It seems many expect a serious investment in this company by institutions and such, but they don't expect a serious commitment from the company. Investors should not have to read the tea leaves, pick up the bread crumbs, connect the dots, or hypothesize about what the company may or may not do. All of that is what is wrong.
That is my point, the next big thing is always right around the corner, and when it is revealed, it only leaves more question, with the promise of the big thing still around yet another corner.
Animals are lead into a trap with bait. I'm not saying that is what Anavex is doing, but crumbs aren't a meal either. Do you remember early on when the p3 brain wave or ERP were touted so highly? What happened to that? Now it is gut microbia, and partial test scores. Eventually people get tired of looking around the corner, and if the big thing around the corner is never revealed, who wants to risk it being a bear?
This could be something good, but I personally do not want to risk a significant investment on the hopes that this company has my best interest in mind. Hope is not an investing strategy, and until they provide solid information with a plan to market, why risk it?
Beauty is in the eye of the beholder. Some see beauty where others do not, some see beauty before others realize what beauty is, and others see through "beauty" as proclaimed by others.
What is tiring is the carefully placed bits of information and thier timing. It leaves you wondering what you are actually looking at. Is that gold or fools gold? It definitely keeps this investment alive, albeit moderately. Why did we not get all of the results from the PDD trial? Will the scientific journal include all information? Certainly the FDA will request a review of all of the data.
What was the volume of those trades and why were they interesting?
Isn't that the point of disclosure. We are all entitled to our own opinion, but the factors that sway that opinion are just as important as the opinion itself. Thus the reason for medical trials, everyone thinks they have the cure. Well maybe not everyone, but they will try like heck to spin it that way.
Monday it is.
With 30 something patients and a target population with millions.
So what exactly is the Cabal doing? They are suppressing the share price by trading shares back and forth, somehow losing count, and picking up shares along the way... so they can own more shares to do what?
Dang Cabal can't keep up. Losing money is too hard, so it is easier to ride the share price up... the Cabal owns so many shares that they can't event stay close, I mean they lost track of over 700,000 shares.
Hmm, wonder what LPC is doing? How does the company raise capital again? Must have been caught with too many shares before the drop. Dang Cabal has too many shares. Board of directors has too many shares. Not enough shares for institutions, that's why they aren't buying at such low prices. Cabal convinced institutions to wait for a lower share price, so they can buy shares cheap from the Cabal.
Hmm, seems like someone is testing support. Let off the gas for a little on the buy side and see where it goes.
So, which way will it go on Monday? Seems to be more interest in keeping it over $5 right now. What happens when that pressure goes away?
I think we have a different understanding of strength. The volume in the morning was to the sell side. It is good to see a little support at the end of the day.
So what happens when Anavex dilutes? Is there a discount, and how does that work?
What happened on October 15th?
Volume is shrinking. It bounced (a little) twice, but the volume is getting weaker. It will be interesting today where this closes. The price can move pretty quick when the volume dries up. We still had good volume today, but it was in the wrong direction. Is it oversold yet? Haven't looked.
I agree with this, and so does my account.
Only that large blocks are trading, not that there is pressure in any one direction. What is the clue? There are 2 sides to every trade. The general direction has been down from the presentation. Is someone accumulating? Maybe. Is someone dumping? Maybe. Are MM's playing with this? Probably, but only if they are making money. So what would drive volume? What happens when Anavex dillutes?
It depends on the trade. I have filled block sizes over 20,000 in one trade. I think it depends on the MM's because often the lots do not show on the buy or sell side until time of execution.
Why do you think big blocks are an indication of strength? When I sell blocks over 10,000, they are typically not filled in one order. So how are these an indication of strength vs weakness? Same thing goes the other way as well, if I trade blocks over 10,000 on the buy side, they rarely get filled that way.
Toes almost in the water...
I'm not sure if you notice the stock price, but it is going down. Are you suggesting the MM's are losing money to let institutions buy in cheaper? How does that work?